Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conditions are right for biopharma M&A to break out

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on May 22, 2023 3:50pm

164 Views

Post# 35459296

RE:RE:RE:RE:RE:RE:RE:RE:Conditions are right for biopharma M&A to break out

Quentin,

I do not think they would sell the company for under $2 bil, with good reason. They have stated they expect to be a two ph 3 company by the end of the year. In those indications, with those results, I feel that would easity justify $2 to $4 bil. Plus all the additional prospects for I/O combos is huge.

The CAR-T market along could be worth many billions.

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment